Skip to main content

Table 1 Rectal radiotherapy indicators

From: Multicentre clinical radiotherapy audit in rectal cancer: results of the IROCA project

Diagnostic phase

% patients diagnosed at different hospital

% patients with pre-treatment MRI, pelvic ultrasound, thoraco–abdominal CT

% patients with TNM, MRI staging

Time between biopsy and first visit at RO

Time between first visit at RO department and beginning of radiotherapy

% patients evaluated pre-treatment in RO department clinical session

% patients presented to Multidisciplinary Tumour Board (MTB)

Treatment phase

% patients included in clinical trial

% patients Long Course Radiotherapy (LCRT)

% patients Short Course Radiotherapy (SCRT)

% patients with 3DCRT, VMAT, IMRT

% patients with simultaneous-integrated boost (SIB)

% patients immobilized

% patients completing treatment in the prescribed time

% patients with treatment interruption of EBRT, due to patient-related reasons, due to centre-related reasons, with dose compensation

Overall treatment time (time between first and last day of treatment)

% patients presented to the second MTB, to the MTB after surgery

% patients with restaging MRI, US pelvic, TNM

Pathology report

% patients with post-surgery ypT, ypN staging

% patients with adjuvant chemotherapy

Side effects

Acute (<  6 months) and chronic (≥ 6 months) adverse effects ≥ grade 3

% patients with rectitis, cystitis-urethritis, neutropenia, diarrhea

Patient follow up

Regular follow-up (≥ 2 visits per annum) after the treatment

% patients with relapse, mortality